Levels of ATG5, UBQLN2, ULK1, and LC3 were analyzed in brain specimens of 32 AD, 10 FTD, and 10 DLB patients, and 14 non-demented CTRL subjects. This evidence concerns the gene MAP1LC3A and Alzheimer disease.